Kaivo Biotech

What Kaivo Biotech does

Kaivo Biotech is a Brazilian privately held biopharmaceutical company founded in 1998 and headquartered in Botucatu, São Paulo state. The company focuses on developing new drugs derived from animal venoms for both human and veterinary health applications. Rather than conducting discovery research internally, Kaivo in-licenses patents obtained from advanced academic research at leading universities and coordinates the full downstream lifecycle of each drug candidate. Its stated pipeline is built around innovative biological products that leverage established venom-derived knowledge and techniques.

Operationally, Kaivo acts as a translational and commercialization bridge between academic research centers and the pharmaceutical industry. The company manages regulatory requirements, patent advancement, marketing, logistics, packaging, quality control, and consumer communication for its candidates, supported by staff with extensive experience launching new medical products. Its go-to-market model is B2B, targeting major pharmaceutical industries as customers, with the stated ambition of becoming a relevant source of bio-drugs for those firms. Revenue mechanics, pricing, and contract structures are not publicly disclosed but are described as negotiated through enterprise licensing and supply arrangements, consistent with licensing/royalty and partnership-based pharma economics.

The company maintains an active website and contact infrastructure (Rod. Gastão Dal Farra, Km 6, Botucatu) with 51-100 employees reported, and collaborates with research centers from universities and pharmaceutical industries under what it characterizes as rigorous security and quality norms. No specific named products, clinical-stage assets, funding rounds, customer logos, certifications, or regulatory milestones are disclosed in the public source material, which limits external verification of pipeline maturity and commercial traction.

Name

Kaivo Biotech

Legal name

Kaivo Biotech

Website

https://kaivo.com.br

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Kaivo Biotech is a Brazilian private biotech company that in-licenses animal venom-derived drug patents from academic research and coordinates full-spectrum development and commercialization for human and veterinary pharmaceutical applications.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

Keywords

• Animal venom pharmaceuticals
• Venom-derived drug development
• Biopharmaceutical licensing
• Veterinary biological products
• Translational biotech research

Headquarters

HQ city

Botucatu

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Drug Licensing and Commercialization: Kaivo in-licenses patents from academic research and coordinates all aspects of drug development and commercialization for pharmaceutical industries. Revenue is generated through the development and launch of novel biological products derived from animal venoms for human and veterinary health applications.

Go-to-market motion1 record

Core offering

Kaivo Biotech develops innovative biological products derived from animal venoms for human and veterinary health applications. The company in-licenses patents obtained from advanced academic research and coordinates all aspects of bringing drug candidates to market, including regulatory requirements, marketing, patent advancements, packaging, quality control, consumer communication, and logistics.

Product overview

Kaivo Biotech operates as a biotech company focused on developing and commercializing drugs derived from animal venoms. The company in-licenses patents from academic research and coordinates all aspects of drug development from translational research through market launch, including regulatory compliance, marketing, patent management, packaging, quality control, and distribution. No specific named products or modules are detailed in the available source material; the company describes its pipeline broadly in terms of drug candidates derived from animal venoms for human and veterinary health applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Animal Venom-Derived Drug Pipeline Kaivo's pipeline consists of novel biological drug candidates derived from animal venoms, developed for human and veterinary health applications. The company in-licenses patents from academic research and coordinates all aspects of bringing these drug candidates to market, including regulatory compliance, marketing, patent advancement, packaging, quality control, and logistics. No specific named commercial products are disclosed in the source material.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Research Centers from Universities and Pharma IndustriescoreStrategic or Co-development PartnerKaivo works together with research centers from the best universities and pharma industries to develop its products. The collaboration advances new technologies to enhance current therapies and create new ones, following rigid security norms and good practices. These partnerships provide access to academic research, particularly in the area of animal venom-derived compounds, while Kaivo coordinates translational research and commercialization strategies.

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• Elanco Animal Health: Major animal health company with therapeutic and preventive products for livestock and companion animals. Comparable veterinary pharmaceutical market focus, though broader and more commercially mature than Kaivo's emerging pipeline.
• Zoetis: Largest standalone animal health company globally, offering a broad range of veterinary pharmaceuticals and biologics. Comparable end-market overlap with Kaivo's veterinary drug development, though at much greater commercial maturity.
• Boehringer Ingelheim Animal Health: Major global animal health company with a broad veterinary pharmaceutical and biologics portfolio. Comparable to Kaivo's veterinary health track but at vastly greater scale and with established global commercialization.

Direct peers

• PolyPeptide Group: Global CDMO specializing in peptide manufacturing for pharmaceutical and biotech customers. Overlap with Kaivo's peptide venom-derived therapeutic pipeline at the manufacturing, formulation, and supply layer.
• BTG International (now part of SERB Pharmaceuticals): Historical specialist in antivenom and venom-derived therapeutics including CroFab and DigiFab. BTG's focus on venom-derived drugs makes it the closest direct peer to Kaivo's animal venom biopharmaceutical niche.
• Zealand Pharma: Peptide-based therapeutic developer with multiple clinical-stage assets. While Zealand focuses on synthetic peptides rather than venom-derived, both companies share the peptide therapeutic platform focus and serve similar human health markets.

Regional players

• Eurofarma: Brazilian pharmaceutical company with a broad portfolio across prescription, generics, OTC, and biotechnology products. Comparable as a Brazilian pharma peer addressing similar end markets and operating under ANVISA regulations.
• Cristália: Brazilian pharmaceutical and biotech company with focus on injectables, anesthetics, and biological products. Similar regional footprint and overlap in Brazilian pharmaceutical/biotech development and commercialization.

Others

• Instituto Butantan: Major Brazilian biomedical research center and one of the world's leading producers of antivenoms and vaccines. Acts as both a potential academic partner and a competing public-sector venom-derived biopharmaceutical developer, making it a natural Brazilian ecosystem comparable.
• Charles River Laboratories: Global CRO and preclinical research organization supporting drug discovery and development. Comparable as a potential contract research and development partner for Kaivo's preclinical venom-derived therapeutic programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/kaivobrasil
• LinkedInlinkedin.com/company/kaivobrasil

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kaivo Biotech